Knight Financial Statements From 2010 to 2025

GUD Stock  CAD 6.19  0.02  0.32%   
Knight Therapeutics financial statements provide useful quarterly and yearly information to potential Knight Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Knight Therapeutics financial statements helps investors assess Knight Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Knight Therapeutics' valuation are summarized below:
Knight Therapeutics does not presently have any fundamental ratios for analysis.
Check Knight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Knight Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Knight financial statements analysis is a perfect complement when working with Knight Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Knight Therapeutics Technical models . Check out the analysis of Knight Therapeutics Correlation against competitors.

Knight Therapeutics Company EBITDA Analysis

Knight Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Knight Therapeutics EBITDA

    
  56.82 M  
Most of Knight Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Knight Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Knight Therapeutics reported earnings before interest,tax, depreciation and amortization of 56.82 M. This is 93.52% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all Canada stocks is 98.54% higher than that of the company.

Knight Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Knight Therapeutics's current stock value. Our valuation model uses many indicators to compare Knight Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Knight Therapeutics competition to find correlations between indicators driving Knight Therapeutics's intrinsic value. More Info.
Knight Therapeutics is one of the top stocks in price to earning category among its peers. It also is rated as one of the top companies in revenue category among its peers totaling about  2,451,075  of Revenue per Price To Earning. Comparative valuation analysis is a catch-all model that can be used if you cannot value Knight Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Knight Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Knight Therapeutics Financial Statements

Knight Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Knight Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company was incorporated in 2013 and is headquartered in Montreal, Canada. KNIGHT THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange.

Pair Trading with Knight Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Knight Stock

  0.64BBD-B BombardierPairCorr
  0.54ONEX Onex CorpPairCorr
  0.46MGA Mega UraniumPairCorr
The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.
The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Knight Stock

Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.